Diabetes Mellitus Non-Glucose Monitoring: Point-of-Care Testing

Abstract

Spanish

French

OBJECTIVE:

To review and evaluate reimbursable point-of-care testing devices yielding immediate results, other than glucometers, that are available to evaluate and monitor diabetes and its complications and to describe how pharmacists may use these devices.

DATA SOURCES:

A MEDLINE search (1966-March 2003) was performed using the following search terms: point-of-care systems, clinical diabetes monitoring, decision support systems, glycosylated hemoglobin, and microalbumin. Pertinent company and product Web sites and customer service departments were accessed for information about point-of-care devices and supplies.

STUDY SELECTION AND DATA EXTRACTION:

All descriptive, evaluative, and comparative articles and product information were reviewed, and relevant information was included.

DATA SYNTHESIS:

Diabetes mellitus is a complex, chronic metabolic disease that is a challenging management problem and requires routine monitoring for disease control and screening for complications. Point-of-care tests are available to monitor hemoglobin A_1c, glucose, fructosamine, ketones, lipid profiles, urinary microalbumin concentrations, and alanine aminotransferase concentrations. Many of these tests are Clinical Laboratory Improvement Amendments (CLIA)—waived and, therefore, practical for pharmacists to use in a variety of settings. Tests for measuring sensation are also discussed. Pharmacists should consider each of these tests in the establishment of a comprehensive diabetes care service.

CONCLUSIONS:

The availability of many new point-of-care testing methods creates new opportunities for pharmacists to monitor drug therapy and screen for complications in patients with diabetes. Reimbursement is possible since many of these tests are CLIA-waived.

Keywords

diabetes pharmacy practice point-of-care tests

Get full access to this article

View all access options for this article.

References

American Diabetes Association. Position statement on the economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003; 26 (Suppl 1): 917–32.

Mensing

Boucher

Cypress

Weinger

Mulcahy

Barta

, National standards for diabetes self-management education. Diabetes Care 2000; 23: 682–9.

Coast-Senior

Kroner

Kelly

Trilli

. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998; 32: 636–41. DOI 10.1345/aph.17095

Hogue

Babamoto

Jackson

Cohen

Laitinen

. Pooled results of community pharmacy—based diabetes education programs in underserved communities. Diabetes Spectrum 2003; 16: 129–33.

Cranor

Bunting

Christensen

. The Asheville project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003; 43: 173–84.

Gong

Hasson

Lum

. Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm 1999; 5: 511–5.

Nau

Ponte

. Effects of a community pharmacist—based diabetes patient management program on intermediate clinical outcome measures. J Managed Care Pharm 2002; 8: 48–53.

Kelly

Rodgers

. Implementation and evaluation of a pharmacist-managed diabetes service. J Managed Care Pharm 2000; 6: 448–93.

Sczupak

Conrad

. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977; 34: 1238–42.

10.

Jaber

Halapy

Fernet

Tummalapalli

Diwakaran

. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996; 30: 238–43.

11.

Rosenthal

. Establishing a pharmacy-based laboratory service. J Am Pharm Assoc 2000; 40: 146–52, 154–6.

12.

Sacks

Bruns

Goldstein

Maclaren

McDonald

Parrott

. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 3.436–72.

13.

Package insert. DCA 2000. Elkhart, IN: Bayer Corporation, October 2000.

14.

Package insert. Cholestech GDX. Hayward, CA: Cholestech, June 2002.

15.

Metrika's A1cNow Single Use A1C test. www.A1cnow.com (accessed 2003 Jul 30).

16.

Bry

Chen

Sacks

. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47: 153–63.

17.

Sickle cell disorder. http://gslc.genetics.utah.edu/units/newborn/infosheets/sicklecelldisorder.cfm (accessed 2003 Jul 30).

18.

Goldstein

Little

Lorenz

Malone

Nathan

Peterson

. Tests of glycemia in diabetes. Diabetes Care 1995; 19: 896–909.

19.

Sheetz

King

. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579–88.

20.

Little

Rohlfing

Wiedmeyer

Myers

Sacks

Goldstein

. The national glycohemoglobin standardization program: A five year progress report. Clin Chem 2001; 47: 1985–92.

21.

Little

. Recent progress in glycohemoglobin testing. Diabetes Care 2000; 23: 265–6.

22.

National Glycohemoglobin Standardization Program (NGSP). www.missouri.edu/∼diabetes/ngsp.html (accessed 2003 Jul 30).

23.

Weykamp

Penders

Muskiet

Van der Slik

. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993; 39: 1717–23.

24.

A1cNow clinical accuracy. www.A1cnow.com/3medical/accuracy.html (accessed 2003 Jul 30).

25.

American Diabetes Association. Position statement on test of glycemia in diabetes. Diabetes Care 2003; 26 (Suppl 1): 106–8.

26.

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl 1): 15–35.

27.

Byrne

Tieszen

Hollis

Dornan

New

. Evaluation of an electrochemical sensor for measuring blood ketones. Diabetes Care 2000; 23: 500–3.

28.

CardioChek Analyzer Home Page. www.testsymptomsathome.com/POL01.asp (accessed 2004 Apr 28).

29.

American Diabetes Association. Position statement on diabetic nephropathy. Diabetes Care 2003; 26 (Suppl 1): 94–8.

30.

Mogensen

Keane

Bennett

Jerums

Parving

Passa

, Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080–4.

31.

Zelmanovitz

Gross

Oliveira

Paggi

Tatsch

Azevedo

. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20: 516–9.

32.

Mogensen

Vestbo

Poulsen

Christiansen

Damsgaard

Eisjaer

, Microalbuminuria and potential confounders: A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18: 572–81.

33.

Package insert. Chemstrip Micral dip and read immunoassay for the semi-quantitative determination of microalbuminuria. Indianapolis, IN: Roche Diagnostic Corporation, 2003.

34.

Package insert. Multistix 10 SG. Elkhart, IN: Bayer Corporation, April 1999.

35.

Package insert. Multistix PRO. Elkhart, IN: Bayer Corporation, November 2000.

36.

Package insert. CLINITEK microalbumin reagent strips for determining albumin and creatinine in urine. Elkhart, IN: Bayer Corporation, May 1999.

37.

Package insert. ImmunoDip urinary albumin test. Oxford, CT: Diagnostic Chemicals, September 2002.

38.

Package insert. DCA 2000 microalbumin/creatinine reagent kit. Elkhart, IN: Bayer Corporation, 2000.

39.

Mogensen

Viberti

Peheim

Kutter

Hasslacher

Hofmann

, Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care 1997; 20: 1642–6.

40.

Parsons

Newman

Pugia

Newall

Price

. Performance of a reagent strip device for quantitation of the urine albumin: Creatinine ratio in a point of care setting. Clin Nephrol 1999; 51: 220–7.

41.

LeFloch

Marre

Rodier

Passa

. Interest of Clinitek Microalbumin in screening for microalbuminuria: Results of a multicentre study in 302 diabetic patients. Diabetes Metab 2001; 27: 36–9.

42.

Pugia

Lott

Luke

Shihabi

Wians

Phillips

. Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods. J Clin Lab Anal 1998; 12: 280–4.

43.

Wallace

Pugia

Lott

Luke

Shihabi

Sheehan

, Multisite evaluation of a new dipstick for albumin, protein, and creatinine. J Clin Lab Anal 2001; 15: 231–5.

44.

Package insert. ALT (GPT) alanine aminotransferase test cassette. Hayward, CA: Cholestech LDX, 2002.

45.

Koda-Kimble

Carlisle

. Diabetes mellitus. In: Koda-Kimble

Young

, eds. Applied therapeutics: The clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 48 49–63.

46.

Package insert. Prandin. Princeton, NJ: Novo Nordisk Pharmaceuticals, October 2002.

47.

Package insert. Precose. West Haven, CT: Bayer Corporation, May 2003.

48.

Package insert. Glucophage. Princeton, NJ: Bristol-Myers Squibb, April 2003.

49.

Package insert. Actos. Lincolnshire, IL: Takeda Pharmaceuticals America, July 2002.

50.

Package insert. Avandia. Research Triangle Park, NC: GlaxoSmithKline, March 2003.

51.

Holland

Young

. Interpretation of clinical laboratory tests. In: Koda-Kimble

Young

, eds. Applied therapeutics: The clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 2–14.

52.

How to perform a comprehensive diabetic foot exam. www.ipma.net/members/footfact/PowerPoint.ppt (accessed 2003 Jul 30).

53.

Qualis Health. www.qualishealth.org/medicare_wa2/diabetes/monofilament_foot_exam.pdf (accessed 2003 Jul 30).

54.

Mueller

. Identifying patients with diabetes mellitus who are at risk for lower extremity complications: Use of Semmes—Weinstein monofilaments. Physical Therapy 1996; 76: 68–71.